Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Merck has also decided to end the favezelimab clinical development program
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Subscribe To Our Newsletter & Stay Updated
